6-K - BrainsWay Ltd. | StockGist

AI Analysis

AI-generated analysis. Always verify with the original filing.

BrainsWay Ltd. completed an additional $6 million milestone-based convertible loan to Neurolief Ltd., triggered by FDA Premarket Approval of Neurolief's Proliv™ Rx system for treatment-resistant major depressive disorder, bringing total investment to $11 million. The strategic agreement includes potential further $5 million equity tranche and a call option to acquire Neurolief.

Key Takeaways

1BrainsWay completed $6 million second tranche convertible loan to Neurolief on March 26, 2026

2Investment triggered by FDA PMA for Proliv™ Rx for MDD in adults failing at least one antidepressant

3Total BrainsWay investment in Neurolief to date: $11 million

4Potential third tranche: up to $5 million equity upon revenue-based target

5BrainsWay holds call option to acquire all Neurolief equity at greater of specified enterprise value or revenue multiple

6Neurolief expanded Proliv™ Rx and Relivion® MG access via Veterans Affairs Federal Supply Schedule

Current Report Details

Event Type

Securities Issuance

Disclosure

Voluntary

Variant

6-K

Items Reported

6-K

Current Report on Form 6-K

Securities Issuance

$6.0M

Transaction Details

Material Agreement

Agreement: August 2025 strategic investment transaction
Parties: BrainsWay Ltd., Neurolief Ltd.

•Second tranche $6 million convertible loan triggered by FDA PMA for Proliv™ Rx
•Total invested to date $11 million
•Third tranche up to $5 million equity upon revenue-based target
•Call option to acquire all outstanding equity interests at greater of specified enterprise value or revenue multiple

Exhibits (2)

6-K

FORM 6-K

99.1

PRESS RELEASE